MCID: SBS004
MIFTS: 47

Substance Dependence malady

Categories: Mental diseases

Aliases & Classifications for Substance Dependence

Aliases & Descriptions for Substance Dependence:

Name: Substance Dependence 12 52 14 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9973
NCIt 47 C35458
SNOMED-CT 64 103326000 255338002
UMLS 69 C0439857

Summaries for Substance Dependence

Disease Ontology : 12 A substance-related disorder that involves the continued use of alcohol or other drugs despite problems related to use of the substance.

MalaCards based summary : Substance Dependence is related to personality disorder and schizophrenia. An important gene associated with Substance Dependence is OPRM1 (Opioid Receptor Mu 1), and among its related pathways/superpathways are Peptide ligand-binding receptors and Circadian entrainment. The drugs Ethanol and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, brain and eye, and related phenotypes are behavior/neurological and nervous system

Wikipedia : 71 Substance dependence also known as drug dependence is an adaptive state that develops from repeated drug... more...

Related Diseases for Substance Dependence

Diseases related to Substance Dependence via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 69)
id Related Disease Score Top Affiliating Genes
1 personality disorder 30.1 BDNF CNR1 DRD2 MAOA OPRM1 POMC
2 schizophrenia 29.3 BDNF CNR1 DRD2 DRD5 HTR1B MAOA
3 drug dependence 11.0
4 peripheral vertigo 10.3 OPRD1 OPRK1 OPRM1
5 cervicitis 10.3 OPRD1 OPRK1 OPRM1
6 18p deletion syndrome 10.2 DRD2 OPRD1 OPRM1 SLC6A3
7 pyromania 10.2 DRD2 MAOA SLC6A3
8 colorectal adenocarcinoma 10.2 DRD2 MAOA SLC6A3
9 autoimmune disease of endocrine system 10.2 CNR1 OPRM1 POMC
10 strongyloidiasis 10.2 DRD2 MAOA SLC6A3
11 rectosigmoid junction neoplasm 10.2 CNR1 DRD2 DRD5 SLC6A3
12 galloway-mowat syndrome 10.2 CHRNA3 CHRNA5
13 simultanagnosia 10.2 CNR1 OPRK1 OPRM1 POMC
14 cervical carcinosarcoma 10.2 CNR1 OPRK1 OPRM1 POMC
15 suppurative periapical periodontitis 10.1 DRD2 OPRD1 OPRK1 OPRM1 POMC
16 cytomegalic congenital adrenal hypoplasia 10.1 BDNF DRD2 MAOA
17 chronic conjunctivitis 10.1 BDNF CNR1 DRD2 SLC6A3
18 vascular skin disease 10.1 BDNF CHRNA3 CHRNA5 CNR1
19 postencephalitic parkinson disease 10.1 BDNF DRD2 MAOA
20 hepatitis d 10.1 BDNF DRD2 MAOA SLC6A3
21 cecal benign neoplasm 10.1 DRD2 HTR1B MAOA SLC6A3
22 hemochromatosis, type 2a 10.1 BDNF DRD2 MAOA SLC6A3
23 multiple personality disorder 10.1 BDNF HTR1B MAOA
24 alopecia 10.1 BDNF CNR1 DRD2
25 carotid stenosis 10.1 DRD2 DRD5 MAOA POMC SLC6A3
26 microcephaly 13, primary, autosomal recessive 10.1 DRD2 DRD5 HTR1B MAOA
27 cholesteatoma 10.0 BDNF CNR1 DRD2 POMC SLC6A3
28 keratosis 10.0 BDNF MAOA POMC
29 bipolar disorder 10.0
30 hereditary multiple exostoses 10.0 BDNF CNR1 DRD2 MAOA POMC
31 aortic valve disease 2 10.0 DRD2 DRD5 SLC6A3
32 retinoblastoma 10.0 BDNF DRD2 HTR1B MAOA SLC6A3
33 paraphilia disorder 10.0 BDNF DRD2 MAOA SLC6A3
34 autism spectrum disorder 10.0 BDNF CNR1 DRD5 OPRM1 POMC SLC6A3
35 psychotic disorder 10.0
36 transmitted_by 9.9 CHRNA3 CHRNA5 DRD2 OPRK1 OPRM1 POMC
37 hypoglycemia 9.9 BDNF CNR1 DRD2 OPRD1 OPRK1 OPRM1
38 mucinous adenocarcinoma 9.9 BDNF DRD2 DRD5 HTR1B MAOA SLC6A3
39 basal cell carcinoma 3 9.9 CHRNA3 CHRNA5 CHRNB4 DRD2 MAOA OPRM1
40 antisocial personality disorder 9.9
41 conduct disorder 9.9
42 alexithymia 9.9
43 borderline personality disorder 9.9
44 ellis-van creveld syndrome 9.9 BDNF DRD2 DRD5 HTR1B MAOA SLC6A3
45 benign epilepsy with centrotemporal spikes 9.9 BDNF CNR1 DRD2 HTR1B MAOA POMC
46 alcohol dependence 9.9
47 attention deficit-hyperactivity disorder 9.8
48 pathological gambling 9.7
49 mood disorder 9.7
50 bulimia nervosa 9.6

Graphical network of the top 20 diseases related to Substance Dependence:



Diseases related to Substance Dependence

Symptoms & Phenotypes for Substance Dependence

MGI Mouse Phenotypes related to Substance Dependence:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.21 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD5
2 nervous system MP:0003631 9.97 BDNF CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2
3 integument MP:0010771 9.91 DRD2 OPRD1 OPRK1 OPRM1 POMC SLC6A3
4 digestive/alimentary MP:0005381 9.87 BDNF CHRNA3 CHRNB4 CNR1 DRD2 OPRK1
5 no phenotypic analysis MP:0003012 9.56 BDNF CHRNA3 CNR1 DRD2 HTR1B OPRD1
6 taste/olfaction MP:0005394 8.92 BDNF CNR1 DRD2 SLC6A3

Drugs & Therapeutics for Substance Dependence

Drugs for Substance Dependence (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 526)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Early Phase 1 64-17-5 702
2
Dopamine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 51-61-6, 62-31-7 681
3
Gabapentin Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 60142-96-3 3446
4
Lamotrigine Approved, Investigational Phase 4,Phase 3,Phase 2 84057-84-1 3878
5
Baclofen Approved Phase 4,Phase 3,Phase 2,Phase 1 1134-47-0 2284
6
Cocaine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-36-2 5760 446220
7
Heroin Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 561-27-3 5462328
8
Nicotine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 54-11-5 942 89594
9
Prazosin Approved Phase 4,Phase 3,Phase 2,Phase 1 19216-56-9 4893
10
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
11
Naloxone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 465-65-6 5284596
12
Bupropion Approved Phase 4,Phase 3,Phase 2,Phase 1 34841-39-9, 34911-55-2 444
13
Topiramate Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 97240-79-4 5284627
14
Risperidone Approved, Investigational Phase 4,Phase 2,Phase 1 106266-06-2 5073
15
Methylphenidate Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 113-45-1 4158
16
Amphetamine Approved, Illicit Phase 4,Phase 3,Phase 2,Phase 1 300-62-9 5826 3007
17
Fluoxetine Approved, Vet_approved Phase 4,Phase 3,Phase 2 54910-89-3 3386
18
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
19
Ondansetron Approved Phase 4,Phase 3,Phase 2,Phase 1 99614-02-5 4595
20
Oxytocin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 50-56-6 439302 53477758
21
Methamphetamine Approved, Illicit Phase 4,Phase 2,Phase 3,Phase 1 537-46-2 10836
22
Citalopram Approved Phase 4,Phase 2,Phase 3,Phase 1 59729-33-8 2771
23
Methadone Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 76-99-3 4095
24
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 16590-41-3 5360515
25
Aripiprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 129722-12-9 60795
26
Lorazepam Approved Phase 4,Phase 2 846-49-1 3958
27
Varenicline Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 249296-44-4 5310966
28
Acamprosate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 77337-76-9 71158
29
Buprenorphine Approved, Illicit, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 52485-79-7 40400 644073
30
Biperiden Approved Phase 4,Phase 3,Phase 2 514-65-8 2381
31
Guaifenesin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 93-14-1 3516
32
Carbon monoxide Approved Phase 4,Phase 3,Phase 2,Phase 1 630-08-0 281
33
Carbamazepine Approved, Investigational Phase 4,Phase 2 298-46-4 2554
34
Progesterone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 57-83-0 5994
35
Valproic Acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 99-66-1 3121
36 Piracetam Approved Phase 4,Phase 3,Phase 2 7491-74-9
37
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
38
Buspirone Approved, Investigational Phase 4,Phase 2 36505-84-7 2477
39
Disulfiram Approved Phase 4,Phase 2,Phase 1 97-77-8 3117
40
Zonisamide Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2 68291-97-4 5734
41
Dutasteride Approved, Investigational Phase 4 164656-23-9 152945 6918296
42
Desipramine Approved Phase 4,Phase 3,Phase 2 50-47-5 2995
43
Ketamine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 6740-88-1 3821
44
Paroxetine Approved, Investigational Phase 4,Phase 3 61869-08-7 43815
45
Sertraline Approved Phase 4,Phase 2,Phase 1 79617-96-2 68617
46
Benzocaine Approved Phase 4,Phase 3,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
47
Eszopiclone Approved Phase 4,Phase 1 138729-47-2 969472
48
Pregabalin Approved, Illicit, Investigational Phase 4,Phase 2,Early Phase 1 148553-50-8 5486971
49
Sodium oxybate Approved Phase 4 502-85-2 5360545
50
Oxazepam Approved Phase 4 604-75-1 4616

Interventional clinical trials:

(show top 50) (show all 1756)
id Name Status NCT ID Phase
1 Improving Outcomes in Psychosis Associated With Substance Use Using Aripiprazole Unknown status NCT01155544 Phase 4
2 Improving Substance Use and Clinical Outcomes in Heavy Cannabis Users With Quetiapine Unknown status NCT01153490 Phase 4
3 Cognitive Correlates of Substance Abuse - 11 Unknown status NCT00000346 Phase 4
4 Buprenorphine and Integrated HIV Care Evaluation Unknown status NCT00124358 Phase 4
5 Integrating Buprenorphine Into HIV Treatment Unknown status NCT00241930 Phase 4
6 Efficacy of Caffeine, With and Without Biperiden, as a Maintenance Treatment for Cocaine Dependence Unknown status NCT00495183 Phase 4
7 tDCS as Add on Therapy for Treatment of Tobacco Dependence by Standardized Behaviour Therapy Unknown status NCT01729507 Phase 4
8 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4
9 Trial for the Treatment of Alcohol Dependence Unknown status NCT00120601 Phase 4
10 Menstrual Cycle Effects on Smoking Cessation and Cue Reactivity Unknown status NCT00664755 Phase 4
11 Topiramate for Hospitalized Patients With Alcoholism: a 12-week Study Unknown status NCT01135602 Phase 4
12 Effectiveness of an E-mail Tracking Intervention Among the Continued Abstinence of Tobacco Consumption Unknown status NCT01494246 Phase 4
13 Pharmacologic MRI in Cocaine Addiction Unknown status NCT01652378 Phase 4
14 Acamprosate vs. Placebo in Bipolar Alcoholics Unknown status NCT00466661 Phase 4
15 Treatment of Alcohol Dependence and Comorbid Bipolar Disorder Unknown status NCT01015586 Phase 4
16 Fluoxetine and Bupropion to Treat Patients With Depression and Alcoholism Unknown status NCT00449007 Phase 4
17 Transfer From Methadone to Buprenorphine Maintenance Treatment Using Buprenorphine Patches Unknown status NCT00750217 Phase 4
18 Paroxetine Treatment in Outpatients With Comorbid PTSD and Substance Dependence Completed NCT00330239 Phase 4
19 Chemical Dependency and Smoking Cessation: Patient's Views - 1 Completed NCT00051883 Phase 4
20 Pilot Study of Vyvanse™ In ADHD Adolescents at Risk for Substance Abuse Completed NCT00573534 Phase 4
21 Depakote ER Therapy for Mania Comorbid With Substance Abuse Completed NCT00208195 Phase 4
22 A Randomized Acceptability and Safety Study of Suboxone Induction in Heroin Users (P05042)(COMPLETED) Completed NCT00604188 Phase 4
23 Citicoline for Bipolar 1 Disorder and Cocaine Dependence Completed NCT00619723 Phase 4
24 Seroquel Therapy for Substance Use Disorders Comorbid With Schizophrenia Completed NCT00208143 Phase 4
25 Randomized Trial of Ultrashort Psychotherapy vs Sustained-Release Bupropion for Smoking Cessation Completed NCT00484692 Phase 4
26 Improving Hepatitis C Treatment in Injection Drug Users Completed NCT00148031 Phase 4
27 Bupropion for ADHD in Adolescents With Substance Use Disorder Completed NCT00936299 Phase 4
28 Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14 Completed NCT00015340 Phase 4
29 Integrating Buprenorphine Into the SFGH AIDS Program Completed NCT00263458 Phase 4
30 Abilify Therapy for Reducing Comorbid Substance Abuse Completed NCT00208169 Phase 4
31 Pregnenolone Trial for Depression in Bipolar Disorders or Recurrent Major Depressive Disorder With Substance Abuse Completed NCT00223197 Phase 4
32 Substance Dependent Teens - Impact of Treating Depression Study 1 - 1 Completed NCT00061113 Phase 4
33 Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9 Completed NCT00015275 Phase 4
34 Brain Changes in Stimulant Dependent Subjects - 8 Completed NCT00000343 Phase 4
35 Integration of Buprenorphine Into HIV Clinical Settings - Primary Care Model (PCM) Completed NCT00798538 Phase 4
36 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4
37 Quetiapine for Cocaine Use and Cravings Completed NCT00232336 Phase 4
38 Treatment of Polydrug-Using Opiate Dependents During Withdrawal Completed NCT00367874 Phase 4
39 Disulfiram Combined With Lorazepam for Alcohol Dependence and Anxiety Disorder Completed NCT00721526 Phase 4
40 An Study of Paliperidone Extended-Release Tablets in the Treatment of Methamphetamine Dependence Completed NCT01825928 Phase 4
41 Electronic Cigarettes in Daily Dependent Smokers Completed NCT02108626 Phase 4
42 Injectable Naltrexone Treatment of Alcohol Dependence in Serious Mental Illness (SMI) Completed NCT00453609 Phase 4
43 Methamphetamine Abuse Treatment in Patients With AIDS - 1 Completed NCT00000321 Phase 4
44 Pharmacotherapy and Intensive Treatment - 2 Completed NCT00000218 Phase 4
45 Intensive Outpatient Versus Outpatient Treatment With Buprenorphine Among African Americans Completed NCT01096550 Phase 4
46 Pre-Release VIVITROL for Opioid Dependent Inmates Completed NCT01563718 Phase 4
47 Smoking Cessation in Alcoholism Treatment Completed NCT00000454 Phase 4
48 Effectiveness of Buprenorphine/Naloxone in Reducing Intravenous Buprenorphine Misuse in France ("RIME") Completed NCT00955162 Phase 4
49 Creatine as a Treatment Option for Depression in Methamphetamine Using Females Completed NCT01514630 Phase 4
50 Genetic and Brain Mechanisms of Naltrexone's Treatment Efficacy for Alcoholism Completed NCT00920829 Phase 4

Search NIH Clinical Center for Substance Dependence

Genetic Tests for Substance Dependence

Anatomical Context for Substance Dependence

MalaCards organs/tissues related to Substance Dependence:

39
Testes, Brain, Eye

Publications for Substance Dependence

Articles related to Substance Dependence:

(show top 50) (show all 383)
id Title Authors Year
1
Depression and severity of substance dependence among heroin dependent patients with ADHD symptoms. ( 27997065 )
2017
2
Associations between compulsive buying and substance dependence/abuse, major depressive episodes, and generalized anxiety disorder among men and women. ( 27215919 )
2016
3
The Positive and Negative Syndrome Scale (PANSS): A Three-Factor Model of Psychopathology in Marginally Housed Persons with Substance Dependence and Psychiatric Illness. ( 26999280 )
2016
4
Attention deficit hyperactivity disorder symptoms, type of offending and recidivism in a prison population: The role of substance dependence. ( 27455899 )
2016
5
An association study revealed substantial effects of dominance, epistasis and substance dependence co-morbidity on alcohol dependence symptom count. ( 27151647 )
2016
6
Integrated Exposure-Based Therapy for Co-Occurring Post Traumatic Stress Disorder (PTSD) and Substance Dependence: Predictors of Change in PTSD Symptom Severity. ( 27854264 )
2016
7
Comorbid depression, antisocial personality, and substance dependence: Relationship with delay discounting. ( 26846198 )
2016
8
Mentalization-based therapy adherence and competence stimulates in-session mentalization in psychotherapy for borderline personality disorder with co-morbid substance dependence. ( 27093128 )
2016
9
Lifetime history of traumatic events in a young adult Mexican American sample: Relation to substance dependence, affective disorder, acculturation stress, and PTSD. ( 27569652 )
2016
10
Use of Family CAGE-AID questionnaire to screen the family members for diagnosis of substance dependence. ( 27748296 )
2016
11
Mindfulness-Oriented Recovery Enhancement versus CBT for co-occurring substance dependence, traumatic stress, and psychiatric disorders: Proximal outcomes from a pragmatic randomized trial. ( 26701171 )
2016
12
Which adolescents develop persistent substance dependence in adulthood? Using population-representative longitudinal data to inform universal risk assessment. ( 26620720 )
2016
13
Does Emotion Dysregulation Mediate the Relationship between Early Maltreatment and Later Substance Dependence? Findings of the CANSAS Study. ( 27438781 )
2016
14
A multidimensional education program at substance dependence treatment centers improves patient knowledge and hepatitis C care. ( 27733137 )
2016
15
Disturbing sleep and sleepfulness during recovery from substance dependence in residential rehabilitation settings. ( 27917494 )
2016
16
Emergency department use and hospitalizations among homeless adults with substance dependence and mental disorders. ( 26242968 )
2015
17
Temperament and character dimensions assessed in general population, in individuals with psychoactive substance dependence and in young male conscripts. ( 25687735 )
2015
18
A study of the substance dependence effect of the ethanolic extract and iridoid-rich fraction from Valeriana jatamansi Jones in mice. ( 26600719 )
2015
19
Medical diagnoses associated with substance dependence among inpatients at a large urban hospital. ( 26107402 )
2015
20
Effectiveness of Computer-Assisted Therapy for Substance Dependence Using Breaking Free Online: Subgroup Analyses of a Heterogeneous Sample of Service Users. ( 26543918 )
2015
21
Relationship between drug dreams, affect, and craving during treatment for substance dependence. ( 25700139 )
2015
22
Dissecting ancestry genomic background in substance dependence genome-wide association studies. ( 26267224 )
2015
23
Investigating the factor structure of the Illness Perception Questionnaire-revised for substance dependence among injecting drug users in China. ( 25649986 )
2015
24
Psychoactive Substance Dependence: A Dentist's Challenge. ( 26556258 )
2015
25
Epidemiological Studies of Substance Dependence and Abuse in Adults. ( 26417548 )
2015
26
Metacognitive and Meta-Emotional Styles in Patients With Alcohol and the Other Substance Dependence. ( 26495260 )
2015
27
The advantages and barriers in the implementation of a substance dependence treatment information system (SDTIS). ( 26941816 )
2015
28
Impaired Decision-Making, Higher Impulsivity, and Drug Severity in Substance Dependence and Pathological Gambling. ( 25918968 )
2015
29
Comparing Sensory Information Processing and Alexithymia between People with Substance Dependency and Normal. ( 26885354 )
2015
30
Alcohol-Dependent Subjects Show Different Personality Traits Compared With Subjects With Multiple Substance Dependence: Preliminary Data. ( 26079976 )
2015
31
Association of the OPRM1 Variant rs1799971 (A118G) with Non-Specific Liability to Substance Dependence in a Collaborative de novo Meta-Analysis of European-Ancestry Cohorts. ( 26392368 )
2015
32
Women with comorbid substance dependence and psychiatric disorders in Sweden: a longitudinal study of hospital care utilization and costs. ( 26048811 )
2015
33
Reward salience and risk aversion underlie differential ACC activity in substance dependence. ( 26106528 )
2015
34
Posttraumatic stress disorder symptoms and risky behaviors among trauma-exposed inpatients with substance dependence: The influence of negative and positive urgency. ( 26278196 )
2015
35
The prescription of addiction medications after implementation of chronic care management for substance dependence in primary care. ( 25524751 )
2015
36
The Comorbid and Individual Impacts of Maternal Depression and Substance Dependence on Parenting and Child Behavior Problems. ( 26478656 )
2015
37
Engagement and substance dependence in a primary care-based addiction treatment program for people infected with HIV and people at high-risk for HIV infection. ( 26298399 )
2015
38
A Pilot Study of Seeking Safety in a Sample of German Women Outpatients with Substance Dependence and Posttraumatic Stress Disorder. ( 26514284 )
2015
39
Substance dependence and mental health in northern Iran. ( 24923370 )
2014
40
Typology of Individuals with Substance Dependence Based on a Montreal Longitudinal Catchment Area Study. ( 25124748 )
2014
41
The ability of single screening questions for unhealthy alcohol and other drug use to identify substance dependence in primary care. ( 24411807 )
2014
42
Profiles Associated Respectively with Substance Dependence Only, Mental Disorders Only and Co-occurring Disorders. ( 25433455 )
2014
43
Chronic Care Management for Substance Dependence in Primary Care Among Patients With Co-Occurring Disorders. ( 25219686 )
2014
44
Structural brain differences in alcohol-dependent individuals with and without comorbid substance dependence. ( 25263262 )
2014
45
Emotional and social loneliness in individuals with and without substance dependence disorder. ( 25632385 )
2014
46
Role of Phosphodiesterase 4-Mediated Cyclic AMP Signaling in Pharmacotherapy for Substance Dependence. ( 25159074 )
2014
47
A comparison of substance dependence treatment information system in America, England, and Iran. ( 24741657 )
2014
48
Therapeutic effects of ritual ayahuasca use in the treatment of substance dependence--qualitative results. ( 24830187 )
2014
49
Using spiritually modified cognitive-behavioral therapy in substance dependence treatment: therapists' and clients' perceptions of the presumed benefits and limitations. ( 25369720 )
2014
50
Personal Network Recovery Enablers and Relapse Risks for Women With Substance Dependence. ( 25231945 )
2014

Variations for Substance Dependence

Expression for Substance Dependence

Search GEO for disease gene expression data for Substance Dependence.

Pathways for Substance Dependence

Pathways related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 11)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.63 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD5
2
Show member pathways
12.1 CHRNA3 CHRNB4 DRD2 DRD5 MAOA SLC6A3
3
Show member pathways
11.97 BDNF DRD2 DRD5 HTR1B
4
Show member pathways
11.73 DRD2 DRD5 HTR1B
5
Show member pathways
11.66 CHRNA3 CHRNA5 DRD2
6
Show member pathways
11.63 BDNF DRD2 MAOA SLC6A3
7
Show member pathways
11.54 CHRNA3 CHRNA5 CHRNB4
8 11.51 MAOA OPRD1 OPRM1 POMC
9
Show member pathways
11.46 ADH1A ADH4 MAOA
10
Show member pathways
10.6 ADH4 MAOA
11
Show member pathways
10.22 CHRNA3 CHRNB4

GO Terms for Substance Dependence

Cellular components related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 12)
id Name GO ID Score Top Affiliating Genes
1 synapse GO:0045202 9.83 CHRNA3 CHRNA5 CHRNB4 OPRK1 RGS17
2 integral component of plasma membrane GO:0005887 9.81 CHRNB4 CNR1 DRD2 DRD5 HTR1B OPRD1
3 axon GO:0030424 9.78 CNR1 DRD2 OPRM1 SLC6A3
4 membrane raft GO:0045121 9.71 CNR1 OPRD1 OPRM1 SLC6A3
5 perikaryon GO:0043204 9.67 DRD2 OPRK1 OPRM1
6 postsynaptic membrane GO:0045211 9.67 CHRNA3 CHRNA5 CHRNB4 OPRD1
7 dendrite membrane GO:0032590 9.46 OPRD1 OPRM1
8 axon terminus GO:0043679 9.43 DRD2 OPRD1 OPRK1
9 acetylcholine-gated channel complex GO:0005892 9.13 CHRNA3 CHRNA5 CHRNB4
10 neuron projection GO:0043005 9.1 CHRNB4 OPRD1 OPRK1 OPRM1 RGS17 SLC6A3
11 integral component of membrane GO:0016021 10.32 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2 DRD5
12 plasma membrane GO:0005886 10.13 ADH1A CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2

Biological processes related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 43)
id Name GO ID Score Top Affiliating Genes
1 chemical synaptic transmission GO:0007268 9.88 CHRNA5 DRD5 HTR1B OPRD1 OPRK1 OPRM1
2 neuropeptide signaling pathway GO:0007218 9.84 OPRD1 OPRK1 OPRM1 POMC
3 excitatory postsynaptic potential GO:0060079 9.81 CHRNA3 CHRNA5 CHRNB4 OPRM1
4 phospholipase C-activating G-protein coupled receptor signaling pathway GO:0007200 9.8 OPRD1 OPRK1 OPRM1
5 sensory perception of pain GO:0019233 9.8 CNR1 OPRD1 OPRK1 OPRM1
6 G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger GO:0007187 9.78 CNR1 HTR1B OPRD1 OPRM1
7 adenylate cyclase-inhibiting G-protein coupled receptor signaling pathway GO:0007193 9.77 OPRD1 OPRK1 OPRM1
8 negative regulation of blood pressure GO:0045776 9.75 CNR1 DRD2 DRD5
9 regulation of sensory perception of pain GO:0051930 9.74 OPRD1 OPRK1 OPRM1
10 eating behavior GO:0042755 9.73 OPRD1 OPRK1 OPRM1
11 response to ethanol GO:0045471 9.73 CNR1 DRD2 HTR1B OPRK1 OPRM1 SLC6A3
12 synaptic transmission, cholinergic GO:0007271 9.72 CHRNA3 CHRNA5 CHRNB4
13 regulation of dopamine secretion GO:0014059 9.69 DRD2 HTR1B
14 behavioral response to cocaine GO:0048148 9.69 DRD2 OPRK1
15 response to iron ion GO:0010039 9.68 DRD2 SLC6A3
16 synaptic transmission, dopaminergic GO:0001963 9.68 DRD2 DRD5
17 estrous cycle GO:0044849 9.68 OPRK1 OPRM1
18 regulation of smooth muscle contraction GO:0006940 9.68 CHRNA3 CHRNB4
19 negative regulation of cAMP biosynthetic process GO:0030818 9.67 HTR1B OPRM1
20 behavioral response to ethanol GO:0048149 9.67 DRD2 OPRM1
21 negative regulation of synaptic transmission, glutamatergic GO:0051967 9.67 DRD2 HTR1B
22 sensory perception GO:0007600 9.66 OPRK1 OPRM1
23 prepulse inhibition GO:0060134 9.66 DRD2 SLC6A3
24 phospholipase C-activating dopamine receptor signaling pathway GO:0060158 9.65 DRD2 DRD5
25 regulation of synaptic transmission, GABAergic GO:0032228 9.65 CNR1 DRD2
26 ethanol oxidation GO:0006069 9.65 ADH1A ADH4
27 G-protein coupled receptor internalization GO:0002031 9.64 DRD2 HTR1B
28 behavior GO:0007610 9.64 HTR1B OPRK1
29 adenylate cyclase-activating dopamine receptor signaling pathway GO:0007191 9.63 DRD5 OPRM1
30 adenohypophysis development GO:0021984 9.63 DRD2 SLC6A3
31 opioid receptor signaling pathway GO:0038003 9.63 OPRD1 OPRK1 OPRM1
32 dopamine catabolic process GO:0042420 9.62 MAOA SLC6A3
33 response to morphine GO:0043278 9.62 CNR1 DRD2 OPRK1 OPRM1
34 alcohol metabolic process GO:0006066 9.61 ADH1A ADH4
35 behavioral response to nicotine GO:0035095 9.61 CHRNA3 CHRNA5 CHRNB4
36 negative regulation of dopamine secretion GO:0033602 9.59 CNR1 DRD2
37 synaptic transmission involved in micturition GO:0060084 9.58 CHRNA3 CHRNB4
38 response to nicotine GO:0035094 9.55 CHRNA5 CHRNB4 CNR1 DRD2 SLC6A3
39 adenylate cyclase-inhibiting opioid receptor signaling pathway GO:0031635 9.52 OPRK1 OPRM1
40 locomotory behavior GO:0007626 9.43 CHRNA3 CHRNB4 DRD2 OPRK1 OPRM1 SLC6A3
41 response to cocaine GO:0042220 9.17 CNR1 DRD2 DRD5 HTR1B OPRK1 OPRM1
42 G-protein coupled receptor signaling pathway GO:0007186 10.16 CNR1 DRD2 DRD5 HTR1B OPRD1 OPRK1
43 signal transduction GO:0007165 10.15 ARHGAP28 CHRNA3 CHRNA5 CHRNB4 CNR1 DRD2

Molecular functions related to Substance Dependence according to GeneCards Suite gene sharing:

(show all 15)
id Name GO ID Score Top Affiliating Genes
1 signal transducer activity GO:0004871 9.91 CNR1 DRD2 DRD5 HTR1B OPRD1 OPRM1
2 extracellular ligand-gated ion channel activity GO:0005230 9.67 CHRNA3 CHRNA5 CHRNB4
3 ligand-gated ion channel activity GO:0015276 9.65 CHRNA3 CHRNA5 CHRNB4
4 neuropeptide binding GO:0042923 9.58 OPRD1 OPRK1 OPRM1
5 retinol dehydrogenase activity GO:0004745 9.55 ADH1A ADH4
6 alcohol dehydrogenase (NAD) activity GO:0004022 9.54 ADH1A ADH4
7 acetylcholine binding GO:0042166 9.54 CHRNA3 CHRNA5 CHRNB4
8 alcohol dehydrogenase activity, zinc-dependent GO:0004024 9.52 ADH1A ADH4
9 dopamine neurotransmitter receptor activity GO:0004952 9.51 DRD2 DRD5
10 acetylcholine-gated cation-selective channel activity GO:0022848 9.5 CHRNA3 CHRNA5 CHRNB4
11 dopamine binding GO:0035240 9.43 DRD2 DRD5 SLC6A3
12 acetylcholine receptor activity GO:0015464 9.33 CHRNA3 CHRNA5 CHRNB4
13 opioid receptor activity GO:0004985 9.13 OPRD1 OPRK1 OPRM1
14 drug binding GO:0008144 9.02 CHRNB4 CNR1 DRD2 HTR1B SLC6A3
15 G-protein coupled receptor activity GO:0004930 10 CNR1 DRD2 DRD5 HTR1B OPRD1 OPRK1

Sources for Substance Dependence

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....